CCPortal

浏览/检索结果: 共2条,第1-2条 帮助

限定条件        
已选(0)清除 条数/页:   排序方式:
Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS) 期刊论文
Science Bulletin, 2021, 卷号: 66, 期号: 15
作者:  Jia W.;  Ma J.;  Miao H.;  Wang C.;  Wang X.;  Li Q.;  Lu W.;  Yang J.;  Zhang L.;  Yang J.;  Wang G.;  Zhang X.;  Zhang M.;  Sun L.;  Yu X.;  Du J.;  Shi B.;  Xiao C.;  Zhu D.;  Liu H.;  Zhong L.;  Xu C.;  Xu Q.;  Liang G.;  Zhang Y.;  Li G.;  Gu M.;  Liu J.;  Yuan G.;  Yan Z.;  Yan D.;  Ye S.;  Zhang F.;  Ning Z.;  Cao H.;  Pan D.;  Yao H.;  Lu X.;  Ji L.
收藏  |  浏览/下载:39/0  |  提交时间:2021/09/01
Chiglitazar  Glycemic control  Insulin resistance  PPAR pan-agonist  Type 2 diabetes  
Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2 期刊论文
Science Bulletin, 2020
作者:  Gu C.;  Wu Y.;  Guo H.;  Zhu Y.;  Xu W.;  Wang Y.;  Zhou Y.;  Sun Z.;  Cai X.;  Li Y.;  Liu J.;  Huang Z.;  Yuan Z.;  Zhang R.;  Deng Q.;  Qu D.;  Xie Y.
收藏  |  浏览/下载:24/0  |  提交时间:2021/09/01
ACE2  Protoporphyrin IX  SARS-CoV-2  Verteporfin